In This Article:
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 4, 2019 / Molecular Partners AG (MOLN.SW), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that its partner Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Abicipar at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California, as follows:
Retina Subspecialty Day, Late Breaking - RET 11 - Section VIII: Late Breaking Developments, Part I (Friday, October 11, 4:18 - 4:58 PM; local Pacific Time):
Abicipar for Neovascular Age‐related Macular Degeneration:
Two-Year Results from CEDAR and SEQUOIA Phase 3 Clinical Trials
-
Author/Presenter: Khurana R.
-
Time: 4:34 - 4:39 PM, local Pacific Time
Financial Calendar
| October 31, 2019 | Interim Management Statement Q3 2019 |
| December 12, 2019 | R&D Day in New York |
| February 6, 2020 | Publication of Full-year Results 2019 (unaudited) |
| April 29, 2020 | Annual General Meeting |
http://investors.molecularpartners.com/financial-calendar-and-events/
*DARPin® is a registered trademark owned by Molecular Partners AG
About the DARPin® Difference
DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates can engage more than five targets, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.
With their low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in preclinical development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid and hematological tumors. MP0274, the second-most advanced DARPin® candidate owned by Molecular Partners, binds to Her2 and inhibits downstream signaling, which leads to induction of apoptosis. MP0274 is currently in phase 1. The company's lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its "I/O toolbox" and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.